

Forced Labor in Canadian Supply Chains- Annual Report for 2023

Structure, Activities and Supply Chains

BIOECTRA is an incorporated business head quartered in Prince Edward Island Canada. We are a Contract Development and Manufacturing Organization (CDMO) specializing in clinical-to-commercial scale production capabilities for biologics, synthetic small molecules, pDNA and mRNA, highly potent APIs, and bioreagents. Our supply chains have a global presence with goods originating in Europe, North America, Asia, East Asia, and Southeast Asia.

Policies and Due Diligence Processes

BIOECTRA is upgrading its *Third Party Supplier Code of Conduct* policy to ensure supply chain partners are also committed to the international agreement requirements. Suppliers who do not formally agree with the policy will be disqualified from doing business with BIOECTRA.

All suppliers in the supplier approval program are required to sign off on BIOECTRA's *Third Party Supplier Code of Conduct* policy at regular intervals. In this manner, we will be able to assess potential at risk suppliers before re-approving them as a supply chain partner.

Additional screening has been incorporated into supplier assessments and reassessments to identify potential forced labor risk areas. Where BIOECTRA does not have a direct relationship with a manufacturer and buys goods through distribution channels it invests considerable resources into identifying the suppliers' manufacturing partner or partners. This added scrutiny helps BIOECTRA to identify second tier and third tier forced labor risk in its supply chain.

Potential risks, when discovered, are discussed with suppliers and manufacturers to establish corrective action plans where necessary. When required, BIOECTRA will conduct on-site assessments directly or through suitably vetted third party audit companies to conduct risk assessments and verify business practices.

Where risk exists, suppliers must take immediate corrective action, or they will be disqualified from doing business with BIOECTRA.

BIOECTRA uses the US Department of Labor's Bureau of International Labor Affairs (ILAB) as its main source of information to monitor supply chain risks against supplier reporting for the goods it purchases. Any goods potentially in scope are assessed for origin and risk, in consultation with its supply chain partners. Decisions requiring corrective action are documented within BIOECTRA's Supplier Incident Response (SIR) system to monitor progress and satisfactory closure.

For 2023, BIOECTRA did not identify any incidents of Forced or Child Labor in its supply chain.

Attestation Statement

This report has been approved pursuant to paragraph (4)(a) of Bill S-211, An Act to enact the Fighting Against Forced Labour and Child Labour in Supply Chains Act and to Amend the Customs Tariff.



Signature / Valana Deighan – General Counsel

05/31/2024

Date (MM/DD/YYYY)